In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
Hosted on MSN28d
The TP53 Gene and Its Role in CancerMedically reviewed by Marla Anderson, MD The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...
A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...
A study released by the National Cancer Center Japan has revealed higher rates of mutations in a tumor-suppressing gene, TP53, in Japanese cancer patients compared to those in the United States ...
Panel C shows the variant allele frequency of indicated DNMT3A and SOCS1 mutations in peripheral-blood ... CAR vector integration in TP53, or both to contribute to the development of CAR+ T ...
Spatially resolved protein profiling in pancreatic adenosquamous carcinoma. Age, number of genomic alterations (GA) per tumor, and alteration frequency of select commonly altered genes based on TP53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback